查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1519372

2024-2032 年按类型、治疗、测试类型、最终用户和地区分類的血红蛋白病市场报告

Hemoglobinopathies Market Report by Type, Treatment, Test Type, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 135 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年，全球血红素病市场规模达到 101 亿美元。製药公司、医疗保健提供者和研究机构之间不断加强的策略合作和伙伴关係、日益向个人化医疗的转变以及监管支持和优惠报销政策的实施是推动市场成长的关键因素。

血红蛋白病是一组影响血红蛋白分子的遗传性疾病，而血红素分子对于红血球在全身输送氧气的正常功能至关重要。这些疾病主要可分为两种类型：地中海贫血和血红蛋白异常变异，例如镰状细胞性贫血。地中海贫血是由突变引起的，突变减少了构成血红蛋白的珠蛋白链之一的产生，导致不平衡和随后的贫血。另一方面，镰状细胞性贫血等疾病是由导致血红蛋白分子本身形状或功能异常的突变引起的。异常的形状会导致红血球变得僵硬，使其难以通过小血管，进而影响氧气的分布。它们通常是遗传性的，会导致轻微到严重的症状，包括疲劳、虚弱，在极端情况下还会导致器官损伤。

公众意识的不断增强主要推动了全球市场的发展。专注于血红蛋白疾病的组织在游说政策变革、资金和改善患者护理方面越来越有效。它们对于教育大众、从而增加早期诊断和治疗也至关重要。随着医疗保健系统变得更加强大和便利，诊断和治疗血红蛋白病等特殊疾病的能力也随之增强。新的诊所和医院正在配备先进的诊断技术，从而涵盖更多的患者群体。除此之外，製药公司、医疗保健提供者和研究机构之间的策略合作和伙伴关係也正在推动血红蛋白病产业的成长。此外，对个人化医疗的日益重视是对血红素病市场产生正面影响的另一个因素。个人化医疗涉及根据患者的个别特征制定医疗治疗方案。向个人化医疗的转变正在影响对专业诊断测试和治疗的需求，进一步推动市场成长。此外，监管支持和优惠报销政策的实施正在创造积极的市场前景。

血红素病市场趋势/驱动因素：

血红素疾病盛行率增加

推动血红蛋白疾病产业的最重要驱动因素之一是血红蛋白疾病（如镰状细胞性贫血、地中海贫血和其他罕见变异）盛行率的上升。这些疾病在特定种族群体和地理区域中普遍存在，但由于全球移民模式，它们越来越多地在更广泛的人群中发现。历史上发病率较低的国家现在报告了更多病例，需要改善医疗基础设施来管理这些疾病。随着认识的提高和诊断率的提高，对专门治疗、诊断和管理计划的需求也相应增加。此外，更多的医疗保健提供者正在接受识别和治疗血红蛋白疾病的培训，进一步促进市场成长。所有这些因素都导致对针对血红蛋白疾病的药物、诊断设备、基因检测试剂盒和专门医疗服务的需求增加，推动了该行业的成长。

诊断和治疗方面的技术进步

血红蛋白疾病产业的另一个重要驱动力是诊断方法和治疗方面的技术进步。透过新生儿筛检和先进的诊断工具（包括高效液相层析 (HPLC) 和分子技术）进行早期诊断，可以更好地管理病情。同时，治疗方法的进步，包括基因治疗、CRISPR 技术和改进的药物配方，也为更有效地管理血红蛋白疾病铺平了道路。这些创新不仅提高了患者的治疗效果，也为市场参与者投资研发提供了动力。随着科技的发展，我们可以预见更准确、更快速的诊断工具和潜在的治疗方法，从而推动产业更大的需求和扩张。

政府措施和资助

政府的努力也是血红蛋白病产业的重要市场驱动力。世界各国政府越来越认识到血红蛋白疾病对公共卫生的影响，并正在製定有针对性的计划来应对这些问题。此外，资助研究、公众宣传活动以及将血红蛋白病筛检纳入国家医疗保健计划也是此类倡议的例子。这些步骤不仅提高了诊断率，而且使更多人群更容易获得治疗。也为製药公司和研究机构开发治疗方法提供特别补助和财政支持。此类措施和对该行业的资金注入极大地促进了需求和供应，促进了市场成长。

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球血红素疾病市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：按类型

  • 地中海型贫血
    • 市场走向
    • 关键环节
      • 阿尔法地中海贫血
      • β地中海型贫血
    • 市场预测
  • 镰形血球贫血症
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 7 章：市场区隔：按处理方式

  • 输血
    • 市场走向
    • 市场预测
  • 干细胞移植
    • 市场走向
    • 市场预测
  • 止痛药
    • 市场走向
    • 市场预测
  • 抗生素
    • 市场走向
    • 市场预测
  • ACE抑制剂
    • 市场走向
    • 市场预测
  • 羟基脲
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 8 章：市场区隔：按测试类型

  • 红血球 (RBC) 计数
    • 市场走向
    • 市场预测
  • 基因检测
    • 市场走向
    • 市场预测
  • 高效液相层析 (HPLC)
    • 市场走向
    • 市场预测
  • 血红素等电聚焦 (Hb IEF)
    • 市场走向
    • 市场预测
  • 血红素电泳 (Hb ELP)
    • 市场走向
    • 市场预测
  • 血红素溶解度测试
    • 市场走向
    • 市场预测

第 9 章：市场区隔：按最终用户

  • 医院和诊所
    • 市场走向
    • 市场预测
  • 诊断实验室
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 10 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 11 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 12 章：价值链分析

第 13 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 14 章：价格分析

第15章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Bio-Rad Laboratories Inc.
    • bluebird bio Inc.
    • Bristol-Myers Squibb Company
    • Danaher Corporation
    • Emmaus Life Sciences Inc.
    • Gamida-Cell Ltd.
    • Global Blood Therapeutics Inc.
    • Novartis AG
    • PerkinElmer Inc.
    • Pfizer Inc.
    • Prolong Pharmaceuticals LLC
    • Sangamo Therapeutics Inc.
    • Sysmex Corporation
Product Code: SR112024A5123

The global hemoglobinopathies market size reached US$ 10.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 21.3 Billion by 2032, exhibiting a growth rate (CAGR) of 8.5% during 2024-2032. The rising strategic collaborations and partnerships among pharmaceutical companies, healthcare providers, and research institutions, the growing shift toward personalized medicine, and the implementation of regulatory support and favorable reimbursement policies are among the key factors driving the market growth.

Hemoglobinopathies are a group of genetic disorders that affect the hemoglobin molecule, which is crucial for the proper function of red blood cells in carrying oxygen throughout the body. These disorders can be categorized mainly into two types: thalassemias and abnormal hemoglobin variants, such as sickle cell anemia. Thalassemias result from mutations that reduce the production of one of the globin chains that make up hemoglobin, leading to an imbalance and subsequent anemia. On the other hand, conditions such as sickle cell anemia are caused by mutations that lead to abnormal shapes or functions of the hemoglobin molecule itself. The abnormal shapes can cause red blood cells to become rigid, making it difficult for them to travel through small blood vessels, thereby affecting oxygen distribution. They are often inherited and can result in symptoms ranging from mild to severe, including fatigue, weakness, and in extreme cases, organ damage.

The growing public awareness majorly drives the global market. Organizations focused on hemoglobinopathies are increasingly effective at lobbying for policy changes, funding, and improved patient care. They are also crucial in educating the public, thereby increasing early diagnosis and treatment. As healthcare systems become more robust and accessible, the capability to diagnose and treat specialized conditions, such as hemoglobinopathies also increases. New clinics and hospitals are being equipped with advanced diagnostic technologies, thereby reaching a larger patient population. Along with this, strategic collaborations and partnerships among pharmaceutical companies, healthcare providers, and research institutions are also driving the growth of the hemoglobinopathies industry. In addition, the growing emphasis on personalized medicine is another factor that impacts the hemoglobinopathies market positively. Personalized medicine involves tailoring medical treatment to individual patient characteristics. The shift toward personalized medicine is influencing the demand for specialized diagnostic tests and treatments, further driving market growth. Moreover, the implementation of regulatory support and favorable reimbursement policies is creating a positive market outlook.

Hemoglobinopathies Market Trends/Drivers:

Increasing prevalence of hemoglobin disorders

One of the most significant drivers propelling the hemoglobinopathies industry is the rising prevalence of hemoglobin disorders such as sickle cell anemia, thalassemias, and other rare variants. These disorders are prevalent in specific ethnic groups and geographical regions, but due to global migration patterns, they are increasingly found in a more widespread population. Countries with historically low incidence rates are now reporting more cases, necessitating improved healthcare infrastructure to manage these conditions. As awareness grows and diagnosis rates increase, there is a corresponding rise in demand for specialized treatments, diagnostics, and management plans. Additionally, more healthcare providers are being trained to recognize and treat hemoglobinopathies, further facilitating market growth. All these factors contribute to increased needs for medication, diagnostics equipment, genetic testing kits, and specialized healthcare services tailored for hemoglobinopathies, thereby driving the industry's growth.

Technological advancements in diagnosis and treatment

Another significant driver for the hemoglobinopathies industry is the technological advancements in both diagnostic methods and treatments. Earlier diagnosis through newborn screenings and sophisticated diagnostic tools including High-Performance Liquid Chromatography (HPLC) and molecular techniques have led to better management of the condition. Along with this, advancements in treatment methods, including gene therapy, CRISPR technology, and improved drug formulations, are also paving the way for more effective management of hemoglobin disorders. These innovations not only enhance patient outcomes but also provide an impetus for market players to invest in research and development. As the technology evolves, we can anticipate more accurate, quicker diagnostic tools and potentially curative therapies, driving greater demand and expansion in the industry.

Government Initiatives and Funding

Governmental efforts are also significant market drivers for the hemoglobinopathies industry. Various governments worldwide are increasingly acknowledging the public health impact of hemoglobin disorders and are setting up targeted programs to deal with them. In addition, funding for research, public awareness campaigns, and inclusion of hemoglobinopathy screening in national healthcare plans are examples of such initiatives. These steps not only increase the rate of diagnosis but also make treatments more accessible to a larger population. Special grants and financial support for pharmaceutical companies and research institutions for developing treatments are also available. Such initiatives and financial injections into the sector significantly bolster both demand and supply, facilitating market growth.

Hemoglobinopathies Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on type, treatment, test type and end user.

Breakup by Type:

Thalassemia

Alpha Thalassemia

Beta Thalassemia

Sickle Cell Disease

Others

Sickle cell disease accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the type. This includes thalassemia (alpha thalassemia and beta thalassemia), sickle cell disease, and others. According to the report, sickle cell disease represented the largest segment.

The market for treating sickle cell disease (SCD), a type of hemoglobinopathy, is experiencing robust growth due to the rising incidence and awareness of SCD, particularly in African, Middle Eastern, and South Asian populations. Additionally, advancements in diagnostic techniques, including high-performance liquid chromatography (HPLC) and genetic screening are enabling earlier and more accurate detection, increasing the demand for targeted treatments. In addition, government initiatives have also played a pivotal role by incorporating SCD screenings in national healthcare plans and providing funding for research. In addition, the emergence of innovative treatment options such as gene therapies and CRISPR technology offer potential curative solutions, attracting significant investment in the sector. Furthermore, positive regulatory frameworks and reimbursement policies make treatments more accessible, thereby expanding the market.

Breakup by Treatment:

Blood Transfusion

Stem-cell Transplantation

Analgesics

Antibiotics

ACE Inhibitors

Hydroxyurea

Others

A detailed breakup and analysis of the market based on the treatment has also been provided in the report. This includes blood transfusion, stem-cell transplantation, analgesics, antibiotics, ace inhibitors, hydroxyurea, and others.

The demand for blood transfusion treatment in the hemoglobinopathies industry is primarily driven by its essential role in managing severe cases of disorders, such as thalassemia and sickle cell disease. Along with this, the increasing prevalence of these conditions amplifies the need for regular transfusions, thereby fueling market growth. In addition, technological advancements in blood screening and storage have also contributed to safer and more efficient transfusion processes. Governmental initiatives, such as organized blood donation campaigns and reimbursement policies, make this treatment more accessible and cost-effective for patients. In addition, the growing interest in stem-cell transplantation as a potentially curative treatment for hemoglobinopathies, including thalassemia and sickle cell disease is a notable market driver. Moreover, technological advancements have made these procedures safer and more effective, drawing increased investment and research focus. Governmental backing in the form of grants and regulatory approval fast-tracks also bolster this sector.

On the other hand, the growing awareness and advocacy for advanced treatment options have led to higher demand for stem-cell transplantation, further propelling market growth in the hemoglobinopathies industry. Apart from this, the demand for analgesics in the hemoglobinopathies industry is driven by chronic pain. Increasing awareness and diagnosis rates further provide a boost to this market segment. The need for antibiotics in the hemoglobinopathies industry is driven by frequent bacterial infections in patients, thereby stimulating the demand for effective treatment options. Furthermore, the market for ACE inhibitors in the hemoglobinopathies industry is propelled by their role in managing kidney complications in patients.

Breakup by Test Type:

Red Blood Cell (RBC) Count

Genetic Testing

High Performance Liquid Chromatography (HPLC)

Hemoglobin Isoelectric Focusing (Hb IEF)

Hemoglobin Electrophoresis (Hb ELP)

Hemoglobin Solubility Test

The report has provided a detailed breakup and analysis of the market based on the test type. This includes red blood cell (RBC) count, genetic testing, high performance liquid chromatography (HPLC), hemoglobin isoelectric focusing (Hb IEF), hemoglobin electrophoresis (Hb ELP), and hemoglobin solubility test.

In the hemoglobinopathies industry, the market drivers for the red blood cell (RBC) count test type are significant. Hemoglobinopathies, including conditions, such as sickle cell anemia and thalassemia, necessitate frequent monitoring of RBC counts to assess disease severity and treatment efficacy. As awareness of these disorders grows, so does the demand for accurate diagnostic tools. Moreover, advancements in healthcare technology have led to more accessible and cost-effective RBC count testing methods. The combination of increased disease awareness and improved diagnostic capabilities positions the RBC count test as a critical component of the hemoglobinopathies industry, driving its market growth. Along with this, genetic testing is a key market driver in the hemoglobinopathies industry, enabling precise disease identification and personalized treatment strategies, and fostering growth and innovation.

On the other hand, high-performance liquid chromatography (HPLC) is a crucial driver in the hemoglobinopathies industry, providing precise hemoglobin analysis, enhancing diagnostics, and fostering industry advancement. Apart from this, hemoglobin isoelectric focusing (Hb IEF) plays a pivotal role in the hemoglobinopathies industry by offering precise hemoglobin analysis, driving diagnostic accuracy, and industry growth. In confluence with this, hemoglobin electrophoresis (Hb ELP) is a cornerstone in the hemoglobinopathies industry, providing precise hemoglobin analysis, driving diagnostic accuracy, and fostering industry growth. Furthermore, hemoglobin solubility testing is a critical driver in the hemoglobinopathies industry, offering efficient diagnosis and aiding in disease management, contributing to industry growth.

Breakup by End User:

Hospitals and Clinics

Diagnostics Laboratories

Others

A detailed breakup and analysis of the market based on the end user has also been provided in the report. This includes hospitals and clinics, diagnostics laboratories, and others.

Diagnostics laboratories serve as a pivotal end user in the hemoglobinopathies industry, driving growth due to their central role in disease diagnosis and management. In addition, the increasing prevalence of hemoglobinopathies worldwide necessitates a higher volume of diagnostic tests, including hemoglobin analysis and genetic testing. Furthermore, ongoing research and development efforts focus on enhancing the accuracy and efficiency of diagnostic tools, further elevating the significance of diagnostics laboratories. Their expertise and technology contribute significantly to advancing our understanding of hemoglobin disorders and tailoring treatment approaches, solidifying their status as key market drivers in this industry.

On the contrary, hospitals and clinics represent crucial end users in the hemoglobinopathies industry, actively driving growth and advancement. These healthcare facilities are frontline providers of care to individuals affected by hemoglobin disorders. The growing awareness of these conditions, coupled with an increasing patient population, leads to a higher demand for diagnostic tests, genetic counseling, and specialized treatments. Hospitals and clinics play a pivotal role in providing comprehensive care, driving the need for improved diagnostic tools and therapeutic interventions. Their prominence as end users reinforces their impact as significant market drivers in the hemoglobinopathies industry.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest hemoglobinopathies market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America stands as a dynamic and influential region in the hemoglobinopathies industry, driven by the region's commitment to healthcare excellence and rigorous standards. It fuels the demand for cutting-edge diagnostic tools and therapeutic interventions. The prevalence of hemoglobin disorders, particularly sickle cell disease, within diverse populations, including African Americans and Hispanic communities, places North America at the forefront of research, diagnosis, and treatment.

Additionally, the region's robust research and development ecosystem, consisting of academic institutions, pharmaceutical companies, and biotechnology firms, fosters innovation in hemoglobinopathy diagnostics and therapies. This research-driven environment continually introduces novel diagnostic methods and treatment modalities, stimulating market growth. Furthermore, advocacy efforts and government initiatives aimed at improving healthcare access for individuals with hemoglobinopathies amplify the demand for diagnostic testing and specialized care. These initiatives include newborn screening programs and policies supporting early diagnosis and intervention.

Competitive Landscape:

The key players are investing heavily in research and development to discover new diagnostic tests, therapies, and treatment modalities. They aim to enhance the accuracy of diagnostic tools and develop innovative treatments that can improve the quality of life for individuals with hemoglobin disorders. Along with this, companies are continually developing and improving diagnostic tests for hemoglobinopathies, including advancements in techniques, such as genetic testing, high-performance liquid chromatography (HPLC), hemoglobin electrophoresis (Hb ELP), and hemoglobin isoelectric focusing (Hb IEF) is positively influencing the market. In addition, pharmaceutical companies in the hemoglobinopathies market work on the development of new therapies, including gene therapies, gene editing technologies (e.g., CRISPR), and small molecule drugs, which act as another growth-inducing factor. Furthermore, the widespread adoption of cutting-edge technologies, such as artificial intelligence and machine learning, for data analysis and improving diagnostic accuracy is contributing to the market.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Bio-Rad Laboratories Inc.

bluebird bio Inc.

Bristol-Myers Squibb Company

Danaher Corporation

Emmaus Life Sciences Inc.

Gamida-Cell Ltd.

Global Blood Therapeutics Inc.

Novartis AG

PerkinElmer Inc.

Pfizer Inc.

Prolong Pharmaceuticals LLC

Sangamo Therapeutics Inc.

Sysmex Corporation

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Recent Developments:

In August 2022, bluebird bio Inc. disclosed information on its U.S. commercial infrastructure to facilitate quick access to ZYNTEGLO, which includes a creative, outcomes-based contract offering and a thorough patient care programme.

In June 2022, Precision BioSciences, Inc. announced that it has signed an agreement (the "Agreement") with Novartis Pharma AG for an exclusive global in vivo gene editing research and development partnership and licence.

In December 2021, Emmaus Life Sciences Inc. released information on Endari(R), a brand name for the business' prescription L-glutamine oral powder used to treat sickle cell illness.

Key Questions Answered in This Report

  • 1. What was the size of the global hemoglobinopathies market in 2023?
  • 2. What is the expected growth rate of the global hemoglobinopathies market during 2024-2032?
  • 3. What has been the impact of COVID-19 on the global hemoglobinopathies market?
  • 4. What are the key factors driving the global hemoglobinopathies market?
  • 5. What is the breakup of the global hemoglobinopathies market based on the type?
  • 6. What is the breakup of the global hemoglobinopathies market based on the treatment?
  • 7. What are the key regions in the global hemoglobinopathies market?
  • 8. Who are the key players/companies in the global hemoglobinopathies market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hemoglobinopathies Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Thalassemia
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Alpha Thalassemia
      • 6.1.2.2 Beta Thalassemia
    • 6.1.3 Market Forecast
  • 6.2 Sickle Cell Disease
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Treatment

  • 7.1 Blood Transfusion
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Stem-cell Transplantation
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Analgesics
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Antibiotics
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 ACE Inhibitors
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Hydroxyurea
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Others
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast

8 Market Breakup by Test Type

  • 8.1 Red Blood Cell (RBC) Count
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Genetic Testing
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 High Performance Liquid Chromatography (HPLC)
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Hemoglobin Isoelectric Focusing (Hb IEF)
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Hemoglobin Electrophoresis (Hb ELP)
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Hemoglobin Solubility Test
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals and Clinics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Diagnostics Laboratories
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Bio-Rad Laboratories Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 bluebird bio Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Bristol-Myers Squibb Company
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Danaher Corporation
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Emmaus Life Sciences Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
    • 15.3.6 Gamida-Cell Ltd.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
    • 15.3.7 Global Blood Therapeutics Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
    • 15.3.8 Novartis AG
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 PerkinElmer Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Pfizer Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Prolong Pharmaceuticals LLC
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
    • 15.3.12 Sangamo Therapeutics Inc.
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 Sysmex Corporation
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Hemoglobinopathies Market: Major Drivers and Challenges
  • Figure 2: Global: Hemoglobinopathies Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Hemoglobinopathies Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Hemoglobinopathies Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Hemoglobinopathies Market: Breakup by Treatment (in %), 2023
  • Figure 6: Global: Hemoglobinopathies Market: Breakup by Test Type (in %), 2023
  • Figure 7: Global: Hemoglobinopathies Market: Breakup by End User (in %), 2023
  • Figure 8: Global: Hemoglobinopathies Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Hemoglobinopathies (Thalassemia) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Hemoglobinopathies (Thalassemia) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Hemoglobinopathies (Sickle Cell Disease) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Hemoglobinopathies (Sickle Cell Disease) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Hemoglobinopathies (Other Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Hemoglobinopathies (Other Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Hemoglobinopathies (Blood Transfusion) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Hemoglobinopathies (Blood Transfusion) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Hemoglobinopathies (Stem-cell Transplantation) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Hemoglobinopathies (Stem-cell Transplantation) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Hemoglobinopathies (Analgesics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Hemoglobinopathies (Analgesics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Hemoglobinopathies (Antibiotics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Hemoglobinopathies (Antibiotics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Hemoglobinopathies (ACE Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Hemoglobinopathies (ACE Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Hemoglobinopathies (Hydroxyurea) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Hemoglobinopathies (Hydroxyurea) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Hemoglobinopathies (Other Treatments) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Hemoglobinopathies (Other Treatments) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Hemoglobinopathies (Red Blood Cell (RBC) Count) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Hemoglobinopathies (Red Blood Cell (RBC) Count) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Hemoglobinopathies (Genetic Testing) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Hemoglobinopathies (Genetic Testing) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Hemoglobinopathies (High Performance Liquid Chromatography-HPLC) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Hemoglobinopathies (High Performance Liquid Chromatography-HPLC) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Hemoglobinopathies (Hemoglobin Isoelectric Focusing-Hb IEF) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Hemoglobinopathies (Hemoglobin Isoelectric Focusing-Hb IEF) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Hemoglobinopathies (Hemoglobin Electrophoresis-Hb ELP) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Hemoglobinopathies (Hemoglobin Electrophoresis-Hb ELP) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Global: Hemoglobinopathies (Hemoglobin Solubility Test) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Global: Hemoglobinopathies (Hemoglobin Solubility Test) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Global: Hemoglobinopathies (Hospitals and Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Global: Hemoglobinopathies (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Global: Hemoglobinopathies (Diagnostics Laboratories) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Global: Hemoglobinopathies (Diagnostics Laboratories) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Global: Hemoglobinopathies (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Global: Hemoglobinopathies (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: North America: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: North America: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: United States: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: United States: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Canada: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Canada: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Asia-Pacific: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Asia-Pacific: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: China: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: China: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Japan: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Japan: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: India: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: India: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: South Korea: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: South Korea: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Australia: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Australia: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Indonesia: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Indonesia: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Others: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Others: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Europe: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Europe: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Germany: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Germany: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: France: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: France: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: United Kingdom: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: United Kingdom: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Italy: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Italy: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Spain: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Spain: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Russia: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Russia: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Others: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Others: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Latin America: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: Latin America: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 87: Brazil: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 88: Brazil: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 89: Mexico: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 90: Mexico: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 91: Others: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 92: Others: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 93: Middle East and Africa: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 94: Middle East and Africa: Hemoglobinopathies Market: Breakup by Country (in %), 2023
  • Figure 95: Middle East and Africa: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 96: Global: Hemoglobinopathies Industry: SWOT Analysis
  • Figure 97: Global: Hemoglobinopathies Industry: Value Chain Analysis
  • Figure 98: Global: Hemoglobinopathies Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hemoglobinopathies Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Hemoglobinopathies Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Hemoglobinopathies Market Forecast: Breakup by Treatment (in Million US$), 2024-2032
  • Table 4: Global: Hemoglobinopathies Market Forecast: Breakup by Test Type (in Million US$), 2024-2032
  • Table 5: Global: Hemoglobinopathies Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 6: Global: Hemoglobinopathies Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Hemoglobinopathies Market: Competitive Structure
  • Table 8: Global: Hemoglobinopathies Market: Key Players